- The use of artificial intelligence by third-party payers to deny insurance claims, as well as broader development and use of augmented intelligence in healthcare;
- Addressing sustainable payment for community practices;
- Research handling of de-identified patient data;
- Ramifications and further steps in addressing the Change Healthcare cyberattack and outage and impact on practices;
- Biosimilar use rates and addressing related pharmacy benefit manager abuses;
- FDA regulation of biosimilars;
- Extension of Medicare reimbursement for certain telemedicine services;
- Accountability and transparency in graduate medical education funding;
- Insurer accountability when prior authorization harms patients; and
- Efforts to reform Medicare Part B drug reimbursement to promote affordability and practice sustainability.
Resolutions are introduced and considered by the ACR based on its positions and policies, and the work of ACR committees and the Board of Directors. The ACR’s delegation to the AMA House of Delegates consists of Gary Bryant, MD (Delegate and Delegation Chair), Eileen Moynihan, MD (Delegate), Cristina Arriens, MD (Alternate Delegate), Colin Edgerton, MD (Alternate Delegate), Luke Barre, MD (Young Physician Section representative), Christina Downey, MD (Young Physician Section representative), and Rami Diab, MD (Resident and Fellows Section representative).
The ACR encourages rheumatologists to join or renew membership in the AMA so this work may continue. Input on the AMA delegation’s work on behalf of the rheumatology community—along with questions or suggestions for this House of Delegates meeting—can be directed to [email protected]. The ACR offers individualized assistance to ACR and ARP members. If you are experiencing specific issues with payers or have other insurance, coding, billing or practice concerns, write to [email protected].
